News Novo Nordisk obesity drug linked to rare cause of sight loss The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
News 23andMe founder isn't giving up her bid to regain control 23andMe founder Anne Wojcicki is hoping to make a fresh bid for the genetic testing firm, riding out a takeover deal with Regeneron.
News Trump backs Biden-era abortion pill defence The Trump administration has intervened in a long-running lawsuit over the abortion pill mifepristone.
News Sun Pharma overturns block on alopecia drug launch in US Sun Pharma successfully removed an injunction on the launch of its Leqselvi for alopecia areata, a common form of hair loss, in the US.
News Jazz pays $145m to resolve Xyrem antitrust disputes Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.
News Third time not so lucky in J&J's bid to end talc liability Johnson & Johnson's third attempt to use bankruptcy proceedings to settle lawsuits claiming its talc-based products harmed consumers has failed.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.